CytoMed Therapeutics Ltd

Our legal and commercial name is CytoMed Therapeutics Limited. We are a public company limited by shares incorporated on March 9, 2018 in Singapore. On January 19, 2023, we converted from a private company limited by shares incorporated in Singapore, known as CytoMed Therapeutics Pte. Ltd. to a public company limited by shares pursuant to the provisions of the Singapore Companies Act. As a public company limited by shares incorporated in Singapore, we are governed by the Companies Act 1967 of Singapore. As of the date of this annual report, we are a holding company incorporated in Singapore which oversees our operations in Malaysia. We conduct our business activities primarily through our subsidiaries in Malaysia, CytoMed Malaysia and IPSC Depository. We expect to conduct more research and clinical trial activities in Singapore through CytoMed moving forward. Other than CytoMed Malaysia and IPSC Depository, our subsidiaries have minimal operations. Effective on January 17, 2023, our shareholders and directors approved a 1-for-380.83 reverse split of its Ordinary Shares pursuant to which the shareholders received one (1) Ordinary Share for every 380.83 Ordinary Shares held as of such date. Our principal executive office in Singapore is located at 1 Commonwealth Lane, #08-22, Singapore 149544. Our telephone number is +65 6250 7738. Our agent for service of process in the United States is Puglisi & Associates whose address is 850 Library Avenue, Newark, Delaware 19711. We file annual reports and other information with the SEC.